Sanofi India Ltd. engages in the manufacturing and distribution of pharmaceutical drugs. The company is headquartered in Mumbai, Maharashtra and currently employs 3,530 full-time employees. The firm is primarily engaged in the business of manufacturing and trading of drugs and pharmaceuticals. The company offers a range of medicines and supplements for treatment of diabetes (both insulin and orals), cardiology, thrombosis, epilepsy, allergies, and infections. The company has two manufacturing sites, one in Hyderabad and one in Goa. Its geographical segments include India, Singapore, and Others. The company sells its products through independent distributors primarily in India. The company also manufactures its products through third party manufacturers. The different types of dosage forms include tablets, capsules (hard and soft), eye/ear drops, ampoules, vials, creams, and ointment. Its brands include Lantus, Allegra, and Combiflam. Its vaccine products include Adacel, Avaxim 80U/160U, FluQuadri, Hexaxim, Menactra, Tetraxim, Vaxigrip, Stamaril, Shanvac-B and ShanTT. Its consumer healthcare products include Allegra, Allegra nasal, and Avil.
Loading chart…
Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:
The headline call - descriptive label, conviction, and the synthesis behind it.
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Forensic and governance risk pointers, severity-ranked.
Solvency and earnings-quality score.
Quarter-by-quarter earnings-call briefs - what changed and why.
23 fields couldn't be derived. The company was scraped before the cash-flow and balance-sheet rows were captured. Re-running an analysis will refresh these.